KeyBank National Association
NBIX icon

KeyBank National Association’s Neurocrine Biosciences NBIX Stock Holding History

KeyBank National Association’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$322K Sell
1,912
-705
-27% -$105K ﹤0.01% 1105
2026
Q1 		$345K Sell
2,617
-216
-8% -$28.7K ﹤0.01% 996
2025
Q4 		$402K Sell
2,833
-115
-4% -$16.7K ﹤0.01% 913
2025
Q3 		$414K Sell
2,948
-112
-4% -$15.2K ﹤0.01% 876
2025
Q2 		$385K Sell
3,060
-502
-14% -$57.6K ﹤0.01% 879
2025
Q1 		$394K Buy
3,562
+467
+15% +$59.2K ﹤0.01% 856
2024
Q4 		$422K Sell
3,095
-493
-14% -$61K ﹤0.01% 856
2024
Q3 		$413K Buy
3,588
+531
+17% +$72.8K ﹤0.01% 866
2024
Q2 		$421K Buy
3,057
+1,435
+88% +$197K ﹤0.01% 801
2024
Q1 		$224K Sell
1,622
-2,008
-55% -$274K ﹤0.01% 1017
2023
Q4 		$478K Sell
3,630
-399
-10% -$45.9K ﹤0.01% 760
2023
Q3 		$453K Buy
4,029
+315
+8% +$33.2K ﹤0.01% 729
2023
Q2 		$350K Sell
3,714
-1,939
-34% -$189K ﹤0.01% 831
2023
Q1 		$572K Sell
5,653
-1,036
-15% -$108K ﹤0.01% 648
2022
Q4 		$799K Sell
6,689
-876
-12% -$103K ﹤0.01% 520
2022
Q3 		$803K Sell
7,565
-219
-3% -$22.2K ﹤0.01% 501
2022
Q2 		$759K Buy
7,784
+1,031
+15% +$95.2K ﹤0.01% 527
2022
Q1 		$633K Sell
6,753
-2,521
-27% -$214K ﹤0.01% 642
2021
Q4 		$790K Buy
9,274
+7
+0.1% +$644 ﹤0.01% 661
2021
Q3 		$889K Buy
9,267
+1,143
+14% +$108K ﹤0.01% 598
2021
Q2 		$791K Sell
8,124
-538
-6% -$51.6K ﹤0.01% 644
2021
Q1 		$842K Sell
8,662
-1,223
-12% -$128K ﹤0.01% 637
2020
Q4 		$947K Sell
9,885
-42
-0.4% -$4.06K ﹤0.01% 545
2020
Q3 		$955K Buy
9,927
+4,868
+96% +$563K 0.01% 497
2020
Q2 		$617K Buy
+5,059
New +$559K ﹤0.01% 614

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

KeyBank National Association's NBIX Position: Q2 2026 in Review

KeyBank National Association reduced its Neurocrine Biosciences (NBIX) stake by 27% in Q2 2026, selling an estimated $105K and leaving 1,912 shares worth $322K. The position accounts for ﹤0.01% of the portfolio, ranked #1105.

KeyBank National Association first reported a position in NBIX in Q2 2020 and has held it in 25 quarters since. The position peaked at $955K in Q3 2020. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • KeyBank National Association held 1,912 shares of Neurocrine Biosciences worth $322K as of Q2 2026.
  • KeyBank National Association sold 705 Neurocrine Biosciences shares in Q2 2026, an estimated $105K.
  • Neurocrine Biosciences made up ﹤0.01% of KeyBank National Association's portfolio in Q2 2026, its #1105 holding.
  • KeyBank National Association first reported a position in Neurocrine Biosciences in Q2 2020 and has held it in 25 quarters since.
  • KeyBank National Association's Neurocrine Biosciences position peaked at $955K in Q3 2020.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on KeyBank National Association's 13F filing for Q2 2026, filed 28 Jul 2026.